Early Metformin Use May Lower Long COVID Risk in Adults With Overweight or Obesity
Early metformin use may lower the risk for long COVID among adults with overweight or obesity.
A study published in Clinical Infectious Diseases found that early metformin initiation after COVID-19 infection is associated with a substantially lower 1-year risk for long COVID in adults with overweight or obesity.
Investigators conducted a population-based retrospective cohort study using data from the Clinical Practice Research Datalink Aurum database (England, 2020-2023) to assess the effectiveness of metformin in preventing long COVID in adults with overweight or obesity.
- The study compared patients who initiated metformin within 90 days of infection (≤120-day refill gap) against those who received no treatment.
- The primary outcome was long COVID between 90 and 365 days after COVID-19 diagnosis, with no associated symptoms present in the 180 days before initial infection.
No direct quotes available in the text.
Author's summary: Metformin may reduce long COVID risk in overweight adults.
More News
- TBA, Appraisal, Reverse Mortgage Tools; STRATMOR on AI and Competition; Can the CFPB be Willed Away?
- Sportsnet | The incredible story of Jonathan Toews return to the NHL – Illegal Curve Hockey
- Borrower Monitoring, AI Processing, DPA, Verification Tools; Events and Training; Robots Will do What?
- Barca beat Girona in stoppage timeThe Shillong Times
- This Hawaii Food Truck Turns Butter Garlic Shrimp Into Legend
- Manchester United’s stance on Kobbie Mainoo leaving Old Trafford in January revealed
- Matthijs de Ligt names Man Utd duo who sparked his childhood love for the club
- “Man Utd are quite convinced…” - Fabrizio Romano reveals “complete” star will leave Old Trafford in 2026
- Brewers Go Out With a Whimper in NLCS
- Lakers' preseason darling was sadly included in flurry of roster cuts